UCB Selects Medidata Clinical Cloud® to Support Patient-Centric Drug Development

NEW YORK–(BUSINESS WIRE)– class= »bwalignl »>
Medidata
(NASDAQ:MDSO), the leading global provider of cloud-based solutions and
data analytics for clinical research, today announced that UCB
has selected the Medidata
Clinical Cloud^® as its enterprise technology platform.

The Brussels-based global biopharmaceutical company will leverage
Medidata’s end-to-end cloud platform to improve operational excellence
and better engage patients across UCB’s diverse clinical development
portfolio. As part of the multi-year agreement, UCB plans to utilize
Medidata’s data management and targeted monitoring capabilities with the
goal of improving clinical data quality and availability; and reducing
trial costs and cycle times. UCB also plans to leverage Medidata’s
mobile health (mHealth) solutions to capture more objective, continuous
data in a manner that reduces patient burden and adds value to patient
lives.

“UCB is committed to transforming the lives of people with severe
diseases, and we are leveraging both scientific advances and
cutting-edge technology to do so,” said Tero Laulajainen, Head of Global
Clinical Sciences and Operations (GCSO) at UCB. “The Medidata Clinical
Cloud will help us get an earlier and more complete view of patients
while they undergo therapy, enabling us to explore new models for
clinical development and identify insights to drive future innovation.”

In adopting a single, unified platform, UCB will have faster access to
clinical data and reduced complexity across its pipeline of neurological
and immunological candidates. The global biopharmaceutical company will
leverage multiple solutions within the Medidata Clinical Cloud platform,
including: Medidata
Rave^®, Medidata
Coder^®, Safety
Gateway, and Medidata
TSDV. UCB plans to use Medidata’s mHealth solution for electronic
patient-reported outcomes (ePRO)
on a study-by-study basis.

“UCB’s patient-led, science-driven research and development is making a
meaningful difference in people’s lives, and Medidata is proud to
provide the technology and analytical insights to propel its R&D
efforts,” said Mike Capone, Medidata’s chief operating officer.
« Medidata’s unified cloud platform is transforming global drug
development, and we are uniquely positioned to support the business and
innovation goals of UCB and nearly 850 other life sciences customers.”

Connect with Medidata

• Read our blog, Geeks
  Talk Clinical
• Tweet this: .@UCB_news
  turns to unified @Medidata #tech to improve clinical #data quality,
  enhance #patient engagement & more: http://ow.ly/w61j30bb5J3
• Follow us on Twitter: @Medidata
• Find us on LinkedIn

About UCB

UCB, Brussels, Belgium (www.ucb.com)
is a global biopharmaceutical company focused on the discovery and
development of innovative medicines and solutions to transform the lives
of people living with severe diseases of the immune system or of the
central nervous system. With more than 7,500 people in approximately 40
countries, the company generated revenue of € 4.2 billion in 2016. UCB
is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About Medidata

Medidata
is reinventing global drug and medical device development by creating
the industry’s leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences customers
worldwide, including nearly 850 global pharmaceutical companies,
innovative biotech, diagnostic and device firms, leading academic
medical centers, and contract research organizations.

The Medidata Clinical Cloud^® brings a new level of quality
and efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled clinical
trial data assets provide deep insights that pave the way for future
growth. The Medidata Clinical Cloud is the primary technology solution
powering clinical trials for 17 of the world’s top 25 global
pharmaceutical companies and is used by 16 of the top 20 medical device
developers— from study design and planning through execution, management
and reporting.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170426005624/en/